Our commitment to advancing cancer care with real-world multi-modal oncology data solutions makes us a valuable partner to pharmaceutical companies.
Why NeoGenomics? The data to get things done
Understanding the vital role that data play in precision oncology, NeoGenomics has the scientific expertise and innovation to help pharma companies succeed sooner.
We collect data from our comprehensive clinical test menu that provides a diverse population data set representative of the entire US population, including race, ethnicity, and rural and urban communities. We have over 2 million patient profiles from over 40,000 unique providers across 4,400 healthcare organizations.

We tailor our data to your specific needs throughout the life cycle planning process. Our multi-modal test menu captures a wide variety of various cancer diagnoses and progression throughout the cancer care continuum.

We are one of the largest oncology reference laboratories in the US, utilizing only NeoGenomics data. Our deep diagnostic and testing expertise allows us to focus on customized data solutions.
Other benefits to leveraging NeoGenomics data:
- Custom use cases defined by your specific product goals and development timeline
- Agile delivery methods with collated and distributed data to fit your requirements
- High impact pre-launch planning, including forecasting, prevalence studies, and diagnostic landscape and testing trend analysis
- Oncology and diagnostic expertise tailored to help with product development
- A true partnership in seeking the answers to cancer’s most pressing questions
- Data accuracy derived from an expansive portfolio of NeoGenomics-run oncology tests spanning multiple methodologies

Our national footprint

Our products
NeoEngage: Commercialization support
NeoPixel: Digital image library
NeoAccelerate: Clinical trial optimization
NeoExplore: Sample archive
Check out our latest precision medicine resources
The current testing landscape and emerging therapies

How real-world data (RWD) can be used to support a tumor-agnostic era

Using AI in precision oncology to enhance screening and streamline workflows

The power of clinico-genomic data versus traditional RWD sources

Review our variety of publications, poster presentations, and white papers.

Want to learn more about NeoGenomics’ pharma and oncology data solutions services? Sign up to receive our quarterly newsletter, PharmaConnect.
